|
Allele Symbol Allele Name Allele ID |
Ptch1tm1Hahn targeted mutation 1, Heidi Hahn MGI:3764517 |
||||||||||||||||||||||||||||
| Summary |
6 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice
• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time
• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining
|
|
• after 200 days of tamoxifen treatment tumors are smaller than fully developed basal cell carcinomas and exhibit decreased proliferation indicating regression
|
|
• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice
• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time
• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| basal cell carcinoma | DOID:2513 | J:158915 | ||
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 326 days
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice
• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice
|
|
• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks is 376 days compared with 441 days for control mice
|
|
• hamartomatous gastrointestinal cystic tumors in 4 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
• in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice
• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice
|
|
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
|
|
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
|
|
• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented
• however, the DN4 population is stable after tamoxifen treatment
|
|
• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, circulating B220high, IgD+ B cells are increased compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1tm1Jwnd control mice)
|
|
• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, bone marrow B220low pre-B cells are lower than in Ptch1tm1Jwnd control mice
|
|
• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
|
|
• however, granulocyte-macrophage lineage specification is normal following treatment with tamoxifen
• following treatment with tamoxifen, the Lin-c-kithighSca-1high population is increased while the population of Lin-c-kitlowSca-1low are underrepresented compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
|
|
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
|
|
• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented
• however, the DN4 population is stable after tamoxifen treatment
|
|
• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, circulating B220high, IgD+ B cells are increased compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1tm1Jwnd control mice)
|
|
• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1tm1Jwnd control mice
|
|
• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1tm1Jwnd control mice
|
|
• following treatment with tamoxifen, bone marrow B220low pre-B cells are lower than in Ptch1tm1Jwnd control mice
|
|
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
|
|
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools